Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase NA 1Phase 2 1Phase 1 1

Status

Completed 34Terminated 14Recruiting 10Unknown 9Active not recruiting 8Withdrawn 5Not yet recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 2Sarcoma 1Plasma cell 1Lymphoid 1Genitourinary 1CNS 1

Conditions

Multiple Myeloma 45Recurrence 14Lymphoma 6Neoplasms 5Neoplasms, Plasma Cell 4Lymphoma, Large B-Cell, Diffuse 4Waldenstrom Macroglobulinemia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Immunoglobulin Light-chain Amyloidosis 2Hodgkin Disease 2Glioblastoma 2Amyloidosis 2Wilms Tumor 1Vomiting 1Small Cell Lung Carcinoma 1Sarcoma 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1Ototoxicity 1Osteosarcoma 1Obesity 1Neoplasms, Germ Cell and Embryonal 1Neoplasm, Residual 1Neoplasm Metastasis 1

Interventions

Cisplatin 9pembrolizumab 7Radiosurgery 6Gemcitabine 6Paclitaxel 5Dexamethasone 5Taxes 4Carboplatin 4trametinib 3ibrutinib 3Surveys and Questionnaires 3Standard of Care 3Radiotherapy 3Nivolumab 3Magnetic Resonance Spectroscopy 3Lenalidomide 3Fluorouracil 3Erlotinib Hydrochloride 3Blood Specimen Collection 3Ascorbic Acid 3venetoclax 2veliparib 2tocilizumab 2pazopanib 2obinutuzumab 2naquotinib 2lenvatinib 2fludarabine 2enzalutamide 2Vemurafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Withdrawn × Neoplasms × Dexamethasone × Clear all
NCT03785184 2019-08-28

A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy

AbbVie

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Neoplasms

NCT03334487 2018-12-26

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

AbbVie

Phase 3 Withdrawn
Thoracic

Neoplasms, Small Cell Lung Carcinoma

NCT02382068 2017-11-09

Dexamethasone in Preventing Hearing Loss in Patients Receiving Cisplatin

Ohio State University Comprehensive Cancer Center

Phase NA Withdrawn

Ototoxicity, Neoplasms

NCT01236586 2017-07-02

RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
CNSGenitourinaryLymphoidSarcoma

Brain Neoplasms, Lymphoma, Neoplasms, Wilms Tumor, Sarcoma, Osteosarcoma

NCT00891761 2015-04-17

A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy

GlaxoSmithKline

Phase 3 Withdrawn
Thoracic

Lung Neoplasms, Nausea, Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡